{"id":49889,"date":"2025-07-08T23:06:14","date_gmt":"2025-07-08T23:06:14","guid":{"rendered":"https:\/\/www.europesays.com\/us\/49889\/"},"modified":"2025-07-08T23:06:14","modified_gmt":"2025-07-08T23:06:14","slug":"dallas-biotech-launches-womens-wellness-division-with-wearable-tech-months-after-15m-series-a-dallas-innovates","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/49889\/","title":{"rendered":"Dallas Biotech Launches Women’s Wellness Division With Wearable Tech\u00a0Months After $15M Series A \u00bb Dallas Innovates"},"content":{"rendered":"

OhmBody\u2014a newly launched \u201cscience-forward\u201d women\u2019s wellness division of Dallas-based Spark Biomedical\u2014has released the first wearable device for menstrual care that combines vagus and trigeminal nerve stimulation to provide holistic support for disruptive periods. <\/strong><\/p>\n

The company says its non-invasive, drug-free device is \u201cdesigned to work with the body\u2019s natural nervous system, not against it, delivering real, holistic relief without hormones or invasive procedures.\u201d<\/p>\n

\"\"<\/p>\n

OhmBody wearable neurostimulation device [Photo: OhmBody]<\/p>\n

Aims to reduce cramps, excessive blood loss, and more<\/p>\n

The new device was developed by a cross-functional team of scientists, engineers, and women with lived experience, the company said. By targeting the body\u2019s built-in regulatory systems, OhmBody is said to help reduce cramps, reduce unhealthy amounts of menstrual blood loss, and \u201cprovide support for other disruptive effects of your period like fatigue, gastric discomfort, and emotional fluctuations while supporting balance from the inside out.\u201d<\/p>\n

\u201cWe didn\u2019t create OhmBody to help you \u2018power through\u2019 your cycle. We created it so you don\u2019t have to,\u201d Amy Gaston, VP of strategic growth at OhmBody, said in a statement. \u201cNo more heating pads, doubling up on protection, planning your wardrobe and your life around your period, and pretending everything is fine. It\u2019s time for smarter period care that moves with you.\u201d<\/p>\n

Delivers low-frequency neurostimulation<\/p>\n

The company said OhmBody delivers low-frequency neurostimulation through a discreet earpiece, activating both the vagus and trigeminal nerves\u2014two key players in supporting pain regulation, inflammation,\u00a0 mood, digestion, and blood flow.<\/p>\n

The dual activation aims to help guide the nervous system out of \u201cfight or flight\u201d mode and back toward \u201crest and digest,\u201d the company said, helping the body self-regulate during the most disruptive phase of the menstrual cycle.<\/p>\n

\u00a0In clinical trials, participants reported 88% experienced greater menstrual comfort; an average of 55% reduction in menstrual blood loss, with a 35% reduction on day 1; and\u00a071% felt more emotionally stable, OhmBody reported.<\/p>\n

\u201cOur research demonstrates that targeted neurostimulation can modulate autonomic nervous system activity to help regulate common menstrual symptoms,\u201d said Dr. Navid Khodaparast, PhD, co-founder and chief science officer at Spark Biomedical. \u201cOhmBody leverages this science to provide women with a non-invasive, drug- and hormone-free option for restoring balance and relief during their cycle.\u201d<\/p>\n

Priced at $719, the OhmBody Starter Kit includes a battery-powered neurostimulation device, 7 single-use adhesive earpieces, a connecting cable, and setup essentials, OhmBody said.<\/p>\n

Spark recently raised a $15M Series A<\/p>\n

In April, Spark announced the close of its \u00a0$15 million Series A fundraising round. Led by Waco-based WAVE Ventures and supported by New York\u2019s Pathway to Cures, the funding will accelerate Spark\u2019s development of its bioelectronic treatments and support its core business focuses of neurological health, hemostasis, and women\u2019s health, the company said at the time.<\/p>\n

Founded in 2018, Spark says its technology uses \u201cprecise, mild electrical pulses\u201d to stimulate the vagus and trigeminal nerves, activating the central nervous system to \u201cmodulate pathways, reduce discomfort, and support physiological balance, resulting in non-invasive, drug-free support for a range of conditions. The goal: harnessing the body\u2019s natural response to electrical signals to deliver what Spark calls \u201ctargeted relief\u2014without invasive procedures or pharmaceuticals.\u201d<\/p>\n

Spark\u2019s wearable\u00a0neurostimulation\u00a0device, the Sparrow Therapy System, is being used to supplement traditional drug-based opioid withdrawal therapies<\/a> as an FDA-cleared treatment option. The company is also partnering with the U.S. Air Force<\/a> to explore its device\u2019s ability to reduce motion sickness and spatial disorientation in pilots.<\/p>\n

Don\u2019t miss what\u2019s next. Subscribe\u00a0to\u00a0Dallas\u00a0Innovates.<\/p>\n

Track Dallas-Fort Worth\u2019s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.<\/p>\n

\u00a0<\/p>\n

\tR E A D\u00a0\u00a0 N E X T\t<\/p>\n